诺和诺德 (Novo Nordisk) (NVO) 在 3 期减肥治疗结果令人失望后，其价值损失了 20% 以上

上周，诺和诺德（NVO）市值损失超过五分之一。生物技术投资者对礼来公司（LLY）的临床数据结果反应过度。

Novo Nordisk (NVO) shares dropped sharply last week after the biotechnology company reported Phase 3 results of its next-generation weight loss therapy.

诺和诺德（NVO）生物技术公司公布了其下一代减肥疗法的第三阶段结果后，该公司股价上周大幅下跌。

Investors were left disappointed by the readout, which showed that CagriSemi met the primary endpoint but achieved a weight loss of only up to around 20% in subjects over 68 weeks. This is slightly below that offered by Eli Lilly's (LLY) drug, where patients may lose around 23%.

投资者对结果感到失望，该结果显示 CagriSemi 达到了主要终点，但在 68 周内受试者的体重仅减轻了 20% 左右。这略低于礼来公司 (LLY) 药物提供的效果，患者可能损失约 23%。

Analysts had expected CagriSemi to achieve a weight loss of nearly 25%.

分析师此前预计CagriSemi将实现近25%的减重。

Now, investors are speculating that Eli Lilly and Viking Therapeutics (VKTX) will benefit from Novo's clinical readout.

现在，投资者猜测礼来公司和 Viking Therapeutics (VKTX) 将从 Novo 的临床结果中受益。

In the retail sector, Nike (NKE) shares closed at around $77.00 after the company posted second-quarter results.

在零售领域，耐克 (NKE) 公布第二季度业绩后，其股价收于 77.00 美元左右。

The firm highlighted the need for shareholder patience as it develops its turnaround plan.

该公司强调，在制定扭亏为盈计划时，股东需要保持耐心。

CEO Elliot Hill noted that the company will prioritize the digital channel. More importantly, it will focus on the sports market while drawing down its excess inventory.

首席执行官埃利奥特·希尔指出，公司将优先考虑数字渠道。更重要的是，它将专注于体育市场，同时减少多余的库存。

Bitcoin (BTC-USD) fell sharply from the $105,000 - $108,000 highs seen last week and traded at around $97,290 in response to the Fed signaling fewer interest rate cuts in 2025.

由于美联储暗示 2025 年降息幅度较小，比特币（BTC-USD）从上周 105,000 美元至 108,000 美元的高点大幅下跌，交易价格约为 97,290 美元。

Higher interest rate levels increase the attractiveness of the U.S. dollar, which decreases demand for gold and bitcoin.

较高的利率水平增加了美元的吸引力，从而减少了对黄金和比特币的需求。

However, once the government averts a shutdown, we could see bitcoin bouncing back and finding new record highs.

然而，一旦政府避免关闭，我们可能会看到比特币反弹并创下新的历史高点。